Impact of COVID-19 on the Thyroid Gland: an Update

Overview

Journal Rev Endocr Metab Disord

Publisher Springer

Specialty Endocrinology

Date 2020 Nov 26

PMID 33241508

Citations 131

Authors

Lorenzo Scappaticcio

Fabian Pitoia

Katherine Esposito

Arnoldo Piccardo

Pierpaolo Trimboli

Affiliations

Soon will be listed here.

Abstract

Coronavirus disease 2019 (COVID-19) is the pandemic of the new millennium. COVID-19 can cause both pulmonary and systemic inflammation, potentially determining multi-organ dysfunction. Data on the relationship between COVID-19 and thyroid have been emerging, and rapidly increasing since March 2020. The thyroid gland and the virus infection with its associated inflammatory-immune responses are known to be engaged in complex interplay. SARS-CoV-2 uses ACE2 combined with the transmembrane protease serine 2 (TMPRSS2) as the key molecular complex to infect the host cells. Interestingly, ACE2 and TMPRSS2 expression levels are high in the thyroid gland and more than in the lungs. Our literature search provided greater evidence that the thyroid gland and the entire hypothalamic-pituitary-thyroid (HPT) axis could be relevant targets of damage by SARS-CoV-2. Specifically, COVID-19-related thyroid disorders include thyrotoxicosis, hypothyroidism, as well as nonthyroidal illness syndrome. Moreover, we noticed that treatment plans for thyroid cancer are considerably changing in the direction of more teleconsultations and less diagnostic and therapeutical procedures. The current review includes findings that could be changed soon by new results on the topic, considering the rapidity of worldwide research on COVID-19.

Citing Articles

A 6-Year Retrospective Study in Surgery Patients with Thyroid Diseases in Mureș County, Romania, Before and During the COVID-19 Pandemic.

Catana R, Nechifor-Boila A, Zahan A, Militaru A, Radu G, Borda A Diagnostics (Basel). 2025; 15(3).

PMID: 39941217 PMC: 11816865. DOI: 10.3390/diagnostics15030287.

Endocrine evaluation of patients hospitalized with COVID-19 infection: A cross sectional analyses in tertiary level hospital.

Ghaffar T, Kanwal S, Aamir A, Hadi N Pak J Med Sci. 2024; 40(11):2572-2576.

PMID: 39634891 PMC: 11613404. DOI: 10.12669/pjms.40.11.9340.

Long-Term Impacts of COVID-19 on Thyroid Health: Insights From Clinical Studies.

Syal R, Kaur J, Siddiqui M, Amatul-Raheem H, Suarez C, Bojanki N Cureus. 2024; 16(10):e71469.

PMID: 39544551 PMC: 11560388. DOI: 10.7759/cureus.71469.

Association of COVID-19 with thyroid dysfunction and autoimmune thyroid disease: A retrospective cohort study.

Di J, Ma X, Wu T, Qiao E, Salouti M, Zhong Y J Transl Autoimmun. 2024; 9:100255.

PMID: 39524116 PMC: 11550720. DOI: 10.1016/j.jtauto.2024.100255.

COVID-19 and persistent symptoms: implications for polycystic ovary syndrome and its management.

Zhang S, Wu Y, Mprah R, Wang M Front Endocrinol (Lausanne). 2024; 15:1434331.

PMID: 39429741 PMC: 11486749. DOI: 10.3389/fendo.2024.1434331.

References

Scappaticcio L, Castellana M, Virili C, Bellastella G, Centanni M, Cannavo S . Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis. J Endocrinol Invest. 2019; 43(2):219-229. DOI: 10.1007/s40618-019-01105-7. View

Java A, Apicelli A, Liszewski M, Coler-Reilly A, Atkinson J, Kim A . The complement system in COVID-19: friend and foe?. JCI Insight. 2020; 5(15). PMC: 7455060. DOI: 10.1172/jci.insight.140711. View

Marazuela M, Giustina A, Puig-Domingo M . Endocrine and metabolic aspects of the COVID-19 pandemic. Rev Endocr Metab Disord. 2020; 21(4):495-507. PMC: 7343578. DOI: 10.1007/s11154-020-09569-2. View

Ding Y, He L, Zhang Q, Huang Z, Che X, Hou J . Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol. 2004; 203(2):622-30. PMC: 7167761. DOI: 10.1002/path.1560. View

Chen T, Wu D, Chen H, Yan W, Yang D, Chen G . Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020; 368:m1091. PMC: 7190011. DOI: 10.1136/bmj.m1091. View

Nishihara E, Ohye H, Amino N, Takata K, Arishima T, Kudo T . Clinical characteristics of 852 patients with subacute thyroiditis before treatment. Intern Med. 2008; 47(8):725-9. DOI: 10.2169/internalmedicine.47.0740. View

Pellegrino R, Cooper K, Di Pizio A, Joseph P, Bhutani S, Parma V . Corona Viruses and the Chemical Senses: Past, Present, and Future. Chem Senses. 2020; . PMC: 7239211. DOI: 10.1093/chemse/bjaa031. View

Zhang D, Fu Y, Zhou L, Liang N, Wang T, Del Rio P . Thyroid surgery during coronavirus-19 pandemic phases I, II and III: lessons learned in China, South Korea, Iran and Italy. J Endocrinol Invest. 2020; 44(5):1065-1073. PMC: 7463102. DOI: 10.1007/s40618-020-01407-1. View

Albano D, Bertagna F, Bertoli M, Bosio G, Lucchini S, Motta F . Incidental Findings Suggestive of COVID-19 in Asymptomatic Patients Undergoing Nuclear Medicine Procedures in a High-Prevalence Region. J Nucl Med. 2020; 61(5):632-636. DOI: 10.2967/jnumed.120.246256. View

10.

Ippolito S, Dentali F, Tanda M . SARS-CoV-2: a potential trigger for subacute thyroiditis? Insights from a case report. J Endocrinol Invest. 2020; 43(8):1171-1172. PMC: 7266411. DOI: 10.1007/s40618-020-01312-7. View

11.

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

12.

Chatterjee S, Ghosh R, Biswas P, Dubey S, Guria R, Sharma C . COVID-19: the endocrine opportunity in a pandemic. Minerva Endocrinol. 2020; 45(3):204-227. DOI: 10.23736/S0391-1977.20.03216-2. View

13.

Hercbergs A, Mousa S, Davis P . Nonthyroidal Illness Syndrome and Thyroid Hormone Actions at Integrin αvβ3. J Clin Endocrinol Metab. 2018; 103(4):1291-1295. DOI: 10.1210/jc.2017-01939. View

14.

Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z . Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020; 10(6):783-791. PMC: 7309152. DOI: 10.1158/2159-8290.CD-20-0422. View

15.

Davis P, Lin H, Hercbergs A, Keating K, Mousa S . Coronaviruses and Integrin αvβ3: Does Thyroid Hormone Modify the Relationship?. Endocr Res. 2020; 45(3):210-215. DOI: 10.1080/07435800.2020.1767127. View

16.

Mazziotti G, Sorvillo F, Piscopo M, Morisco F, Cioffi M, Stornaiuolo G . Innate and acquired immune system in patients developing interferon-alpha-related autoimmune thyroiditis: a prospective study. J Clin Endocrinol Metab. 2005; 90(7):4138-44. DOI: 10.1210/jc.2005-0093. View

17.

Falcone R, Grani G, Ramundo V, Melcarne R, Giacomelli L, Filetti S . Cancer Care During COVID-19 Era: The Quality of Life of Patients With Thyroid Malignancies. Front Oncol. 2020; 10:1128. PMC: 7344223. DOI: 10.3389/fonc.2020.01128. View

18.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

19.

Mehanna H, Hardman J, Shenson J, Abou-Foul A, Topf M, AlFalasi M . Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus. Lancet Oncol. 2020; 21(7):e350-e359. PMC: 7289563. DOI: 10.1016/S1470-2045(20)30334-X. View

20.

Ackermann M, Verleden S, Kuehnel M, Haverich A, Welte T, Laenger F . Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020; 383(2):120-128. PMC: 7412750. DOI: 10.1056/NEJMoa2015432. View